Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction

Chemico-Biological Interactions

Volumn 230, Issue , 2015, Pages 9-20

  Nirogi, Ramakrishna ^a   Palacharla, Raghava Choudary ^a   Mohammed, Abdul Rasheed ^a   Manoharan, Arunkumar ^a   Ponnamaneni, Ranjith Kumar ^a   Bhyrapuneni, Gopinadh ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

Author keywords

CYP2B6; Drug interaction; Metabolism based inhibition; Selegiline; Static model

Indexed keywords

AMFEBUTAMONE; CLORGYLINE; CYTOCHROME P450 2B6; EFAVIRENZ; HYDRALAZINE; ISONIAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PHENELZINE; SELEGILINE; TRANYLCYPROMINE; CYP2B6 PROTEIN, HUMAN; CYTOCHROME P450 2B6 INHIBITOR; GLUTATHIONE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC50; INHIBITION KINETICS; LIVER MICROSOME; PREDICTION; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; GESTURE; HYDROXYLATION; METABOLISM;

BUPROPION; CLORGYLINE; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2B6 INHIBITORS; DRUG INTERACTIONS; GLUTATHIONE; HUMANS; HYDROXYLATION; INHIBITORY CONCENTRATION 50; KINESICS; MICROSOMES, LIVER; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PHENELZINE; SELEGILINE;

EID: 84923233590     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.01.028     Document Type: Article

References (50)

1. K.I. Shulman, N. Herrmann, and S.E. Walker Current place of monoamine oxidase inhibitors in the treatment of depression CNS Drugs 27 10 2013 789 797
2. Peter. Riederer, and Gerd. Laux MAO-inhibitors in Parkinson's disease Exp. Neurobiol. 20 1 2011 11 17
3. J.S. Lee, R.S. Obach, and M.B. Fisher Non-P450 mediated oxidative metabolism of xenobiotics in drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development FontisMedia SA 2003 483 539
4. U. Sharma, E.S. Roberts, and P.F. Hollenberg Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline Drug Metab. Dispos. 24 6 1996 669 675
5. U. Sharma, E.S. Roberts, and P.F. Hollenberg Formation of a metabolic intermediate complex of cytochrome P4502B1 by clorgyline Drug Metab. Dispos. 24 11 1996 1247 1253
6. S.F. Muakkassah, and W.C. Yang Mechanism of the inhibitory action of phenelzine on microsomal drug metabolism J. Pharmacol. Exp. Ther. 219 1981 147 155
7. T.M. Polasek, D.J. Elliot, A.A. Somogyi, E.M. Gillam, B.C. Lewis, and J.O. Miners An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid Br. J. Clin. Pharmacol. 61 5 2006 570 584
8. S.F. Muakkassah, W.R. Bidlack, and W.C. Yang Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism Biochem. Pharmacol. 30 12 1981 1651 1658
9. X. Wen, J.S. Wang, P.J. Neuvonen, and J.T. Backman Isoniazid is a mechanism- based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes Eur. J. Clin. Pharmacol. 57 2002 799 804
10. C. Sridar, C. Kenaan, and P.F. Hollenberg Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts Drug Metab. Dispos. 4 2012 2256 2266
11. H. Wang, and L.M. Tompkins CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme Clin. Pharmacol. Ther. 81 2007 pp. 557-6
12. M. Rotger, H. Tegude, S. Colombo, M. Cavassini, H. Furrer, L. Décosterd, J. Blievernicht, T. Saussele, H.F. Günthard, M. Schwab, M. Eichelbaum, A. Telenti, and U.M. Zanger Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals Clin. Pharmacol. Ther. 81 2007 557 566
13. B.A. Ward, J.C. Gorski, D.R. Jones, S.D. Hall, D.A. Flockhart, and Z. Desta The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J. Pharmacol. Exp. Ther. 306 2003 287 300
14. S.R. Penzak, G. Kabuye, P. Mugyenyi, F. Mbamanya, V. Natarajan, R.M. Alfaro, C. Kityo, E. Formentini, and H. Masur Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda HIV Med. 8 2007 86 91
15. S. Asimus, and M. Ashton Artemisinin - a possible CYP2B6 probe substrate? Biopharm. Drug Dispos. 30 2009 265 275
16. L.M. Hesse, K. Venkatakrishnan, M.H. Court, L.L. von Moltke, S.X. Duan, R.I. Shader, and D.J. Greenblatt CYP2B6 mediates the invitro hydroxylation of bupropion: potential drug interactions with other antidepressants Drug Metab. Dispos. 28 2000 1176 1183
17. B.S. Raccor, A.J. Claessens, J.C. Dinh, J.R. Park, D.S. Hawkins, S.S. Thomas, K.W. Makar, J.S. McCune, and R.A. Totah Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation invitro and in vivo Drug Metab. Dispos. 40 2012 54 63
18. C.P. Granvil, A. Madan, M. Sharkawi, A. Parkinson, and I.W. Wainer Role of CYP2B6 and CYP3A4 in the invitro N-dechloroethylation of (R)- and (S)- ifosfamide in human liver microsomes Drug Metab. Dispos. 27 1999 533 541
19. R.S. Obach, L.M. Cox, and L.M. Tremaine Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases human: an invitro study Drug Metab. Dispos. 33 2005 262 270
20. S.K. Bae, S. Cao, K.A. Seo, H. Kim, M.J. Kim, J.H. Shon, K.H. Liu, H.H. Zhou, and J.G. Shin Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes Drug Metab. Dispos. 36 2008 1679 1688
21. J.Y. Chung, S.B. Jang, Y.J. Lee, M.S. Park, and K. Park Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects J. Clin. Pharmacol. 51 2011 53 59
22. M. Hidestrand, M. Oscarson, J.S. Salonen, L. Nyman, O. Pelkonen, M. Turpeinen, and M. Ingelman-Sundberg CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes Drug Metab. Dispos. 29 2001 1480 1484
23. M.H. Court, S.X. Duan, L.M. Hesse, K. Venkatakrishnan, and D.J. Greenblatt Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes Anesthesiology 94 2001 110 119
24. S. Gadel, A. Crafford, K. Regina, and E.D. Kharasch Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6 Drug Metab. Dispos. 41 2013 709 713
25. Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S. Miura, A. Kurihara, N.A. Farid, and T. Ikeda Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel Drug Metab. Dispos. 37 2009 2009 589 593
26. H. Zhang, H. Amunugama, S. Ney, N. Cooper, and P.F. Hollenberg Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme Mol. Pharmacol. 80 2011 839 847
27. R.L. Walsky, and R.S. Obach A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6 Drug Metab. Dispos. 35 2007 2053 2059
28. S. Ekins, M. VandenBranden, B.J. Ring, and S.A. Wrighton Examination of purported probes of human CYP2B6 Pharmacogenetics 7 1997 165 179
29. J.W. Ko, Z. Desta, and D.A. Flockhart Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6 Drug Metab. Dispos. 26 1998 775 778
30. S.R. Faucette, R.L. Hawke, E.L. Lecluyse, S.S. Shord, B. Yan, R.M. Laethem, and C.M. Lindley Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity Drug Metab. Dispos. 28 2000 2000 1222 1230
31. R. Yuan, S. Madani, X.X. Wei, K. Reynolds, and S.M. Huang Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study invitro drug interactions Drug Metab. Dispos. 30 2002 1311 1319
32. M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, and O. Pelkonen Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro Drug Metab. Dispos. 32 6 2004 Jun 626 631
33. S.W. Grimm, H.J. Einolf, S.D. Hall, K. He, H.K. Lim, K.H. Ling, C. Lu, A.A. Nomeir, E. Seibert, K.W. Skordos, G.R. Tonn, R.V. Horn, R.W. Wang, Y.N. Wong, T.J. Yang, and R.S. Obach The conduct of invitro studies to address time- dependent inhibition of drug metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America Drug Metab. Dispos. 37 2009 1355 1370
34. O.A. Fahmi, T.S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation and induction determined in vitro Drug Metab. Dispos. 36 2008 1698 1708
35. FDA, Guidance for industry, Drug Interaction Studies-Study Design, Data analysis, Implications for Dosing, and Labeling Recommendations. < http://www.fda.gov/downloads/drugs/developmentapprovalProcess/DevelopmentResources/DrugInteractionsLabeling/UCM269209.pdf >, 2012.
36. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 pie Drug Metab. Dispos. 34 2006 880 886
37. A.B. Renwick, P.S. Watts, R.J. Edwards, P.T. Barton, I. Guyonnet, R.J. Price, J.M. Tredger, O. Pelkonen, A.R. Boobis, and B.G. Lake Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices Drug Metab. Dispos. 28 2000 1202 1209
38. J. Yang, M. Liao, M. Shou, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates and implications for the prediction of drug interactions Curr. Drug Metab. 9 2008 384 393
39. E.H. Heinonen, V. Myllyla, K. Sotaniemi, R. Lammintausta, J.S. Salonen, M. Anttila, M. Savijarvi, M. Kotila, and U.K. Rinne Pharmacokinetics and metabolism of Selegiline Acta Neurol. Scan. 80 1989 1989 93 99
40. Ho-sang shin Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites Drug Metab. Dispos. 25 1997 657 662
41. M.Z. Sakatis, M.J. Reese, A.W. Harrell, M.A. Taylor, I.A. Baines, L. Chen, J.C. Bloomer, E.Y. Yang, H.M. Ellens, J.L. Ambroso, C.A. Lovatt, A.D. Ayrton, and S.E. Clarke Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds Chem. Res. Toxicol. 25 10 2012 2067 2082 Oct 15
42. K.C. Lee, and J.J. Chen Transdermal selegiline for the treatment of major depressive disorder Neuropsy. Dis. Treat. 3 2007 527 537
43. K. Laine, M. Anttila, Huupponen Risto, O. Maki-Ikola, and E. Heinonen Multiple dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding Clin. Neuropharmacol. 23 2000 22 27
44. A.J. Azzaro, J. Ziemniak, E. Kemper, B.J. Campbell, and C. Vandenberg Selegiline transdermal system: an examination of the potential for CYP450 dependent pharmacokinetic interactions with 3 psychotropic medications J. Clin. Pharmacol. 47 2007 146 158
45. Z.E. Barter, H.K. Crewe, J.R. Kenny, G.T. Tucker, K. Rowland Yeo, What is the contribution of CYP2B6 to bupropion mediated metabolic clearance? Implication for the prediction of CYP2B6 mediated drug-drug interactions, < https://issx.confex.com/issx/12euro/webprogram/paper27340.html >.
46. R.L. Walsky, A.V. Astuccio, and R.S. Obach Evaluation of 227 drugs for invitro inhibition of cytochrome P450 2B6 J. Clin. Pharmacol. 46 2006 1426 1438
47. Simcyp, 2014. Simcyp prediction tools-fu, < https://members.simcyp.com/account/tools/fu/ > (accessed on 9-Oct-2014).
48. Simcyp, 2014. Simcyp prediction tools-fumic < https://members.simcyp.com/account/tools/fu/ > (accessed on 9-Oct-2014).
49. M.S. Varma, R.S. Obach, C. Rotter, H.R. Miller, G. Chang, S.J. Steyn, A. El-Kattan, and M.D. Troutman Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J. Med. Chem. 53 2010 1098 1108
50. Bupropion, < www.mdpoison.com/media/sop/mdpoison.com/publication/toxtidbits/[2014]/june2014toxtidbits.pdf >.